Immunological activation following transcutaneous delivery of HR-gp100 protein.
Vaccine
; 25(23): 4564-70, 2007 Jun 06.
Article
en En
| MEDLINE
| ID: mdl-17493711
Transcutaneous immunization aims at taking advantage of the skin's immune system for the purpose of immunoprotection. In the present study, we evaluated the potential of topical delivery of a recombinant melanoma protein, HR-gp100, derived from a shortened sequence of the native gp100 gene. The protein was applied on the skin, with and without the addition of two forms of heat labile enterotoxin (nLT and LTB). HR-gp100 fused to Haptide, a cell penetrating 20mer peptide (HR-gp100H) was also tested. Topical HR-gp100 and HR-gp100H application on the ears of mice elicited the production of specific antibodies, and transcutaneous delivery to intact human skin induced dose-dependent LC activation. nLT and LTB also activated LC, but did not further increase the activation induced by HR-gp100. These results show that HR-gp100, an antigenic tumor-derived protein, activates the immune system following transcutaneous delivery, as shown by both Langerhans cell activation and induction of antibody production.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Piel
/
Glicoproteínas de Membrana
/
Células de Langerhans
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Vaccine
Año:
2007
Tipo del documento:
Article
País de afiliación:
Israel
Pais de publicación:
Países Bajos